GlassScriptPhysician profile
Maya Rankova
NPI 1881772044
$7,165.44
in general payments reported to CMS, 2019-2025
38 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $904 · 2021: $1,187 · 2022: $1,217 · 2023: $1,086 · 2024: $882 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,583.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $731.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $480.92 | 2019-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $431.78 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $390.23 | 2019-2023 | Farxiga |
| Amgen INC. | $358.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $357.55 | 2020-2024 | |
| Eisai INC. | $328.81 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.26 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $267.35 | 2022 | |
| Amarin Pharma, INC. | $237.19 | 2019-2021 | |
| Allergan, INC. | $233.66 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $197.56 | 2019-2022 | |
| Lilly USA, LLC | $171.86 | 2021-2024 | Mounjaro, Zepbound, Kisunla |
| Sk Life Science, INC. | $124.99 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Rankova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.